Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + VEX in Advanced TNBC
NCT06229067Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab in triple-negative breast cancer (TNBC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06229067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06229067.